Is Atrial Fibrillation a Preventable Disease?

Journal of the American College of Cardiology

Volumn 69, Issue 15, 2017, Pages 1968-1982

  Du, Xin ^a   Dong, Jianzeng ^a   Ma, Changsheng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

diabetes mellitus; hypertension; lifestyle; obesity; prevention; risk factors

Indexed keywords

AMLODIPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; NITRATE; TRANDOLAPRIL;

ACUTE HEART INFARCTION; ALCOHOL ABUSE; BODY MASS; CARDIORESPIRATORY FITNESS; CASE CONTROL STUDY; COHORT ANALYSIS; DYSLIPIDEMIA; EMOTIONAL STRESS; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART FAILURE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIFESTYLE; OBESITY; PAROXYSMAL ATRIAL FIBRILLATION; PERSISTENT ATRIAL FIBRILLATION; PHYSICAL ACTIVITY; POPULATION RESEARCH; POST HOC ANALYSIS; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PULSE PRESSURE; REVIEW; RISK FACTOR; SLEEP DISORDERED BREATHING; SMOKING; TREADMILL EXERCISE; WEIGHT GAIN; ATRIAL FIBRILLATION; HEALTH PROMOTION; ORGANIZATION AND MANAGEMENT; PREVENTIVE HEALTH SERVICE; PROCEDURES;

ATRIAL FIBRILLATION; HEALTH PROMOTION; HUMANS; PREVENTIVE HEALTH SERVICES; RISK FACTORS;

EID: 85017305983     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.02.020     Document Type: Review

References (113)

1. 1 Miyasaka, Y., Barnes, M.E., Gersh, B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota 1980 to 2000, and implications on the projections for future prevalence. Circulation 114 (2006), 119–125.
2. 2 Go, A.S., Hylek, E.M., Phillips, K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285 (2001), 2370–2375.
3. 3 Krijthe, B.P., Kunst, A., Benjamin, E.J., et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 34 (2013), 2746–2751.
4. 4 Chiang, C.E., Wang, K.L., Lip, G.Y., Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 111 (2014), 789–797.
5. 5 Lip, G.Y., Brechin, C.M., Lane, D.A., The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 142 (2012), 1489–1498.
6. 6 Haim, M., Hoshen, M., Reges, O., et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc, 4, 2015, e001486.
7. 7 Chugh, S.S., Havmoeller, R., Narayanan, K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study. Circulation 129 (2014), 837–847.
8. 8 Schnabel, R.B., Yin, X., Gona, P., et al. 50 Year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 386 (2015), 154–162.
9. 9 Svennberg, E., Engdahl, J., Al-Khalili, F., et al. Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation 131 (2015), 2176–2184.
10. 10 Benjamin, E.J., Wolf, P.A., D'Agostino, R.B., et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98 (1998), 946–952.
11. 11 Miyasaka, Y., Barnes, M.E., Petersen, R.C., et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J 28 (2007), 1962–1967.
12. 12 Reddy, V.Y., Akehurst, R.L., Armstrong, S.O., et al. Time to cost-effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAA closure. J Am Coll Cardiol 66 (2015), 2728–2739.
13. 13 Wong, C.X., Brooks, A.G., Leong, D.P., et al. The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: a 15-year study of all hospitalizations in Australia. Arch Intern Med 172 (2012), 739–741.
14. 14 Braunwald, E., Shattuck lecture—cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 337 (1997), 1360–1369.
15. 15 Akesson, A., Larsson, S.C., Discacciati, A., et al. Low-risk diet and lifestyle habits in the primary prevention of myocardial infarction in men: a population-based prospective cohort study. J Am Coll Cardiol 64 (2014), 1299–1306.
16. 16 Chomistek, A.K., Chiuve, S.E., Eliassen, A.H., et al. Healthy lifestyle in the primordial prevention of cardiovascular disease among young women. J Am Coll Cardiol 65 (2015), 43–51.
17. 17 Centers for Disease Control and Prevention. Summary health statistics for U.S. adults: National Health Interview Survey 2012. Vital and Health Statistics. Series 10, Number 260, 2014. Available at: http://www.cdc.gov/nchs/data/series/sr_10/sr10_260.pdf. Accessed February 18, 2017.
18. 18 Djoussé, L., Levy, D., Benjamin, E.J., et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham study. Am J Cardiol 93 (2004), 710–713.
19. 19 Larsson, S.C., Drca, N., Wolk, A., Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. J Am Coll Cardiol 64 (2014), 281–289.
20. 20 Mukamal, K.J., Tolstrup, J.S., Friberg, J., et al. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation 112 (2005), 1736–1742.
21. 21 Sano, F., Ohira, T., Kitamura, A., et al. Heavy alcohol consumption and risk of atrial fibrillation. The Circulatory Risk in Communities Study (CIRCS). Circ J 78 (2014), 955–961.
22. 22 Conen, D., Tedrow, U.B., Cook, N.R., et al. Alcohol consumption and risk of incident atrial fibrillation in women. JAMA 300 (2008), 2489–2496.
23. 23 Frost, L., Vestergaard, P., Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med 164 (2004), 1993–1998.
24. 24 Liang, Y., Mente, A., Yusuf, S., et al., for the ONTARGET and TRANSCEND Investigators. Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease. CMAJ 184 (2012), E857–E866.
25. 25 Drca, N., Wolk, A., Jensen-Urstad, M., et al. Atrial fibrillation is associated with different levels of physical activity levels at different ages in men. Heart 100 (2014), 1037–1042.
26. 26 Drca, N., Wolk, A., Jensen-Urstad, M., et al. Physical activity is associated with a reduced risk of atrial fibrillation in middle-aged and elderly women. Heart 101 (2015), 1627–1630.
27. 27 Azarbal, F., Stefanick, M.L., Salmoirago-Blotcher, E., et al. Obesity, physical activity, and their interaction in incident atrial fibrillation in postmenopausal women. J Am Heart Assoc, 3, 2014, e001127.
28. 28 Karjalainen, J., Kujala, U.M., Kaprio, J., et al. Lone atrial fibrillation in vigorously exercising middle aged men: case-control study. BMJ 316 (1998), 1784–1785.
29. 29 Andersen, K., Farahmand, B., Ahlbom, A., et al. Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. Eur Heart J 34 (2013), 3624–3631.
30. 30 Aizer, A., Gaziano, J.M., Cook, N.R., et al. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol 103 (2009), 1572–1577.
31. 31 Qureshi, W.T., Alirhayim, Z., Blaha, M.J., et al. Cardiorespiratory fitness and risk of incident atrial fibrillation: results from the Henry Ford Exercise Testing (FIT) Project. Circulation 131 (2015), 1827–1834.
32. 32 Khan, H., Kella, D., Rauramaa, R., et al. Cardiorespiratory fitness and atrial fibrillation: a population-based follow-up study. Heart Rhythm 12 (2015), 1424–1430.
33. 33 Pathak, R.K., Elliott, A., Middeldorp, M.E., et al. Impact of Cardiorespiratory Fitness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: the CARDIO-FIT study. J Am Coll Cardiol 66 (2015), 985–996.
34. 34 Eaker, E.D., Sullivan, L.M., Kelly-Hayes, M., et al. Anger and hostility predict the development of atrial fibrillation in men in the Framingham Offspring Study. Circulation 109 (2004), 1267–1271.
35. 35 Eaker, E.D., Sullivan, L.M., Kelly-Hayes, M., et al. Tension and anxiety and the prediction of the 10-year incidence of coronary heart disease, atrial fibrillation, and total mortality: the Framingham Offspring Study. Psychosom Med 67 (2005), 692–696.
36. 36 Cheng, Y.F., Leu, H.B., Su, C.C., et al. Association between panic disorder and risk of atrial fibrillation: a nationwide study. Psychosom Med 75 (2013), 30–35.
37. 37 Torén, K., Schiöler, L., Söderberg, M., et al. The association between job strain and atrial fibrillation in Swedish men. Occup Environ Med 72 (2015), 177–180.
38. 38 Hansson, A., Madsen-Härdig, B., Olsson, S.B., Arrhythmia-provoking factors and symptoms at the onset of paroxysmal atrial fibrillation: a study based on interviews with 100 patients seeking hospital assistance. BMC Cardiovasc Disord, 4, 2004, 13.
39. 39 Lampert, R., Jamner, L., Burg, M., et al. Triggering of symptomatic atrial fibrillation by negative emotion. J Am Coll Cardiol 64 (2014), 1533–1534.
40. 40 Whang, W., Davidson, K.W., Conen, D., et al. Global psychological distress and risk of atrial fibrillation among women: the Women's Health Study. J Am Heart Assoc, 1, 2012, e001107.
41. 41 Suzuki, S., Otsuka, T., Sagara, K., et al. Association between smoking habits and the first-time appearance of atrial fibrillation in Japanese patients: evidence from the Shinken Database. J Cardiol 66 (2015), 73–79.
42. 42 Chamberlain, A.M., Agarwal, S.K., Folsom, A.R., et al. Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm 8 (2011), 1160–1166.
43. 43 Heeringa, J., Kors, J.A., Hofman, A., et al. Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study. Am Heart J 156 (2008), 1163–1169.
44. 44 Dixit, S., Pletcher, M.J., Vittinghoff, E., et al. Secondhand smoke and atrial fibrillation: data from the Health eHeart Study. Heart Rhythm 13 (2016), 3–9.
45. 45 Ng, M., Fleming, T., Robinson, M., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384 (2014), 766–781.
46. 46 Wanahita, N., Messerli, F.H., Bangalore, S., et al. Atrial fibrillation and obesity—results of a meta-analysis. Am Heart J 155 (2008), 310–315.
47. 47 Tedrow, U.B., Conen, D., Ridker, P.M., et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (Women's Health Study). J Am Coll Cardiol 55 (2010), 2319–2327.
48. 48 Wang, T.J., Parise, H., Levy, D., et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 292 (2004), 2471–2477.
49. 49 Conen, D., Tedrow, U.B., Cook, N.R., et al. Birth weight is a significant risk factor for incident atrial fibrillation. Circulation 122 (2010), 764–770.
50. 50 Rosengren, A., Hauptman, P.J., Lappas, G., et al. Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men. Eur Heart J 30 (2009), 1113–1120.
51. 51 Abed, H.S., Wittert, G.A., Leong, D.P., et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 310 (2013), 2050–2060.
52. 52 Pathak, R.K., Middeldorp, M.E., Lau, D.H., et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 64 (2014), 2222–2231.
53. 53 Pathak, R.K., Middeldorp, M.E., Meredith, M., et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol 65 (2015), 2159–2169.
54. 54 Jamaly, S., Carlsson, L., Peltonen, M., et al. Bariatric surgery and the risk of new-onset atrial fibrillation in Swedish obese subjects. J Am Coll Cardiol 68 (2016), 2497–2504.
55. 55 Danaei, G., Finucane, M.M., Lin, J.K., et al., for the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure). National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants. Lancet 377 (2011), 568–577.
56. 56 O'Neal, W.T., Soliman, E.Z., Qureshi, W., et al. Sustained pre-hypertensive blood pressure and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis. J Am Soc Hypertens 9 (2015), 191–196.
57. 57 Conen, D., Tedrow, U.B., Koplan, B.A., et al. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 119 (2009), 2146–2152.
58. 58 Grundvold, I., Skretteberg, P.T., Liestøl, K., et al. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. Hypertension 59 (2012), 198–204.
59. 59 Psaty, B.M., Manolio, T.A., Kuller, L.H., et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96 (1997), 2455–2461.
60. 60 Benjamin, E.J., Levy, D., Vaziri, S.M., et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271 (1994), 840–844.
61. 61 Huxley, R.R., Lopez, F.L., Folsom, A.R., et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 123 (2011), 1501–1508.
62. 62 Watanabe, T., Kawasaki, M., Tanaka, R., et al. Association among blood pressure control in elderly patients with hypertension, left atrial structure and function and new-onset atrial fibrillation: a prospective 2-year study in 234 patients. Hypertens Res 36 (2013), 799–806.
63. 63 Verdecchia, P., Staessen, J.A., Angeli, F., et al., for the Cardio-Sis Investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 374 (2009), 525–533.
64. 64 Mitchell, G.F., Vasan, R.S., Keyes, M.J., et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA 297 (2007), 709–715.
65. 65 Larstorp, A.C., Ariansen, I., Gjesdal, K., et al. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint (LIFE) reduction in hypertension study. Hypertension 60 (2012), 347–353.
66. 66 Roetker, N.S., Chen, L.Y., Heckbert, S.R., et al. Relation of systolic, diastolic, and pulse pressures and aortic distensibility with atrial fibrillation (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol 114 (2014), 587–592.
67. 67 Hansson, L., Lindholm, L.H., Niskanen, L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 (1999), 611–616.
68. 68 Salehian, O., Healey, J., Stambler, B., et al., for the HOPE Investigators. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J 154 (2007), 448–453.
69. 69 Hansson, L., Lindholm, L.H., Ekbom, T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354 (1999), 1751–1756.
70. 70 Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372 (2008), 1174–1183.
71. 71 Haywood, L.J., Ford, C.E., Crow, R.S., et al., for the ALLHAT Collaborative Research Group. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 54 (2009), 2023–2031.
72. 72 Schmieder, R.E., Kjeldsen, S.E., Julius, S., et al., for the VALUE Trial Group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 26 (2008), 403–411.
73. 73 Wachtell, K., Lehto, M., Gerdts, E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45 (2005), 712–719.
74. 74 Pedersen, O.D., Bagger, H., Kober, L., et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100 (1999), 376–380.
75. 75 Pizzetti, F., Turazza, F.M., Franzosi, M.G., et al., for the GISSI-3 Investigators. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 86 (2001), 527–532.
76. 76 Schneider, M.P., Hua, T.A., Böhm, M., et al. Prevention of atrial fibrillation by renin-angiotensin system inhibition: a meta-analysis. J Am Coll Cardiol 55 (2010), 2299–2307.
77. 77 Vermes, E., Tardif, J.C., Bourassa, M.G., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107 (2003), 2926–2931.
78. 78 Maggioni, A.P., Latini, R., Carson, P.E., et al., for the Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149 (2005), 548–557.
79. 79 Ducharme, A., Swedberg, K., Pfeffer, M.A., et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Am Heart J 151 (2006), 985–991.
80. 80 International Diabetes Federation. IDF Diabetes Atlas. 5th ed., 2011, International Diabetes Federation, Brussels, Belgium Available at: www.diabetesatlas.org/component/attachments/?task=download&id=70 Accessed February 18, 2017.
81. 81 Huxley, R.R., Filion, K.B., Konety, S., et al. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 108 (2011), 56–62.
82. 82 Dublin, S., Glazer, N.L., Smith, N.L., et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med 25 (2010), 853–858.
83. 83 Huxley, R.R., Alonso, A., Lopez, F.L., et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart 98 (2012), 133–138.
84. 84 Latini, R., Staszewsky, L., Sun, J.L., et al. Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. Am Heart J 166 (2013), 935–940.e1.
85. 85 Schoen, T., Pradhan, A.D., Albert, C.M., et al. Type 2 diabetes mellitus and risk of incident atrial fibrillation in women. J Am Coll Cardiol 60 (2012), 1421–1428.
86. 86 Fatemi, O., Yuriditsky, E., Tsioufis, C., et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol 114 (2014), 1217–1222.
87. 87 Lopez, F.L., Agarwal, S.K., Maclehose, R.F., et al. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol 5 (2012), 155–162.
88. 88 Alonso, A., Yin, X., Roetker, N.S., et al. Blood lipids and the incidence of atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis and the Framingham Heart Study. J Am Heart Assoc, 3, 2014, e001211.
89. 89 Young-Xu, Y., Jabbour, S., Goldberg, R., et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92 (2003), 1379–1383.
90. 90 Adabag, A.S., Nelson, D.B., Bloomfield, H.E., Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am Heart J 154 (2007), 1140–1145.
91. 91 Vedre, A., Gurm, H.S., Froehlich, J.B., et al., for the GRACE Investigators. Impact of prior statin therapy on arrhythmic events in patients with acute coronary syndromes (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol 104 (2009), 1613–1617.
92. 92 Kulik, A., Singh, J.P., Levin, R., et al. Association between statin use and the incidence of atrial fibrillation following hospitalization for coronary artery disease. Am J Cardiol 105 (2010), 1655–1660.
93. 2 score, statin therapy, and risks of atrial fibrillation. Am J Med 126 (2013), 133–140.
94. 94 Pellegrini, C.N., Vittinghoff, E., Lin, F., et al. Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial. Heart 95 (2009), 704–708.
95. 95 Peña, J.M., MacFadyen, J., Glynn, R.J., et al. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J 33 (2012), 531–537.
96. 96 Rahimi, K., Emberson, J., McGale, P., et al., for the PROSPER Executive. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ, 342, 2011, d1250.
97. 97 Peppard, P.E., Young, T., Barnet, J.H., et al. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 177 (2013), 1006–1014.
98. 98 Gami, A.S., Pressman, G., Caples, S.M., et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 110 (2004), 364–367.
99. 99 Gami, A.S., Hodge, D.O., Herges, R.M., et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 49 (2007), 565–571.
100. 100 Monahan, K., Storfer-Isser, A., Mehra, R., et al. Triggering of nocturnal arrhythmias by sleep-disordered breathing events. J Am Coll Cardiol 54 (2009), 1797–1804.
101. 101 Kanagala, R., Murali, N.S., Friedman, P.A., et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation 107 (2003), 2589–2594.
102. 102 Fein, A.S., Shvilkin, A., Shah, D., et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 62 (2013), 300–305.
103. 103 Schmitt, J., Duray, G., Gersh, B.J., et al. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 30 (2009), 1038–1045.
104. 104 Stamboul, K., Zeller, M., Fauchier, L., et al. Incidence and prognostic significance of silent atrial fibrillation in acute myocardial infarction. Int J Cardiol 174 (2014), 611–617.
105. 105 Cha, Y.M., Redfield, M.M., Shen, W.K., et al. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 109 (2004), 2839–2843.
106. 106 Zakeri, R., Chamberlain, A.M., Roger, V.L., et al. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 128 (2013), 1085–1093.
107. 107 Campuzano, O., Brugada, R., Genetics of familial atrial fibrillation. Europace 11 (2009), 1267–1271.
108. 108 Khera, A.V., Emdin, C.A., Drake, I., et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med 375 (2016), 2349–2358.
109. 109 Schnabel, R.B., Sullivan, L.M., Levy, D., et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 373 (2009), 739–745.
110. 110 Alonso, A., Krijthe, B.P., Aspelund, T., et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc, 2, 2013, e000102.
111. 111 Lubitz, S.A., Yin, X., Lin, H., et al., for the AFGen Consortium. Genetic risk prediction of atrial fibrillation. Circulation, 2016 Oct 28 [E-pub ahead of print].
112. 112 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al., for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 133 (2016), e38–e360.
113. 113 Bi, Y., Jiang, Y., He, J., et al., for the 2010 China Noncommunicable Disease Surveillance Group. Status of cardiovascular health in Chinese adults. J Am Coll Cardiol 65 (2015), 1013–1025.